Table 2. Patient characteristics.
| Patient characteristics | PVE (N=51) | Complete ALPPS (N=12) | Partial ALPPS (N=9) | P value |
|---|---|---|---|---|
| Age (years), median [IQR] | 64 [56–70] | 69 [61–72] | 61 [59–64] | 0.292 |
| Sex (male/female) | 32/19 | 7/5 | 4/5 | 0.645 |
| BMI (kg/m2), median [IQR] | 24.4 [22.8–26.6] | 25.8 [24.8–29.1] | 22.5 [22.3–25.5] | 0.034 |
| BSA (m2), median [IQR] | 1.94 [1.77–2.02] | 1.92 [1.72–2.24] | 1.80 [1.60–2.00] | 0.489 |
| Tumor type, n [%] | 0.001 | |||
| CRLM | 17 [33] | 11 [92] | 6 [67] | |
| HCC | 5 [10] | 0 [0] | 2 [22] | |
| Biliary | 26 [51] | 1 [8] | 0 [0] | |
| PHC | 20 [39] | 1 [8] | 0 [0] | |
| IHC | 6 [12] | 0 [0] | 0 [0] | |
| Benign | 2 [4] | 0 [0] | 1 [11] | |
| Other malignant | 1 [2] | 0 [0] | 0 [0] | |
| Neo-adjuvant chemotherapy, n [%] | 17 [33] | 9 [75] | 6 [67] | 0.015 |
| Cycles, median [IQR] | 4 [3–6] | 6 [4–11] | 7 [4–9] | 0.046 |
| Biliary drainage in patients with PHC (number/total PHC) | 17/20 | 1/1 | 0/0 | |
| ASA, n [%] | 0.035 | |||
| ≤2 | 46 [90] | 10 [83] | 5 [56] | |
| >2 | 5 [10] | 2 [17] | 4 [44] | |
| FRL, n [%] | 0.172 | |||
| Left (segments 1–4) | 28 [55] | 7 [58] | 8 [89] | |
| Left lateral (segments 1–3) | 23 [45] | 5 [42] | 1 [11] |
PVE, portal vein embolization; ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; BMI, body mass index; BSA, body surface area; CRLM, colorectal liver metastasis; HCC, hepatocellular carcinoma; PHC, perihilar cholangiocarcinoma; IHC, intrahepatic cholangiocarcinoma; ASA, American Society of Anesthesiologists; FRL, future remnant liver; IQR, interquartile range.